COMy 2022 | Risk stratification in multiple myeloma
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses highlights from the first session at the COMy 2022 meeting which reviewed the importance and methods used to assess disease risk in multiple myeloma. Dr Ghobrial comments on the first presentation which looked at the definition of risk in multiple myeloma and how important it is for individualized care of patients. The next presentation during the session focused on the genomics of multiple myeloma and the importance of further understanding the most appropriate treatment options for patients with high-risk disease. This session also covered how imaging is used to assess the bone marrow environment, and how current modalities could be improved. Finally, Dr Ghobrial mentions her talk on the genomics in monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) to assess patients for risk of progression to multiple myeloma. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Disclosures
Irene Ghobrial, MD, discloses links to Janssen, Sanofi, BMS, GSK, Karyopharm and Binding Site.
